Newsletter | January 24, 2025

01.24.25 -- How Investment Experience Informs One Biotech Leadership Approach

NEW PODCAST EPISODE

The Future of NK Cell Therapy for Autoimmune Disease with Artiva Biotherapeutics' Christopher Horan

Christopher Horan, Chief Technical Operations Officer at Artiva Biotherapeutics, joins Cell & Gene: The Podcast to explore the unique advantages of natural killer (NK) cells over T cells in autoimmune therapies. Host Erin Harris dives into why NK cells are ideal for scalable, ‘off-the-shelf’ treatments and highlights Artiva’s innovative “manufacturing first” strategy for production. Together, they uncover how these breakthroughs are shaping the future of cell therapy. Listen now!

FEATURED VIDEO

Risk Mitigation With MeiraGTx's Zandy Forbes, Ph.D.

Zandy Forbes, Ph.D., combines science and finance expertise to manage biotech risk. With a Ph.D. from Oxford, a postdoc fellowship, and over a decade as a Wall Street healthcare investor, she now leads Meira GTx as President & CEO. On Business of Biotech, she discusses how her investment experience informs her approach to biotech leadership.

INDUSTRY INSIGHTS

Unlock The Secrets Of Managing CTR In A Complex Development Landscape

Lost in the CTR maze? Watch this webinar to get your burning questions answered by industry experts. Ask about vendor coordination, CTIS integration, and EU strategies.

Reducing Environmental Impact At All Stages Of The Medicine Journey

Explore how utilizing technologies like AI and digital twinning can inform decision-making at the R&D stage and how to optimize the delivery of the final drug product to patients with greener logistics.

Nitrosamine Impurities Deadline: Are Your Products Compliant?

The FDA nitrosamine contamination guidance set a deadline of August 1, 2025, for all drug manufacturers and market authorization holders to comply fully with the NDSRI limits set.

CONTRIBUTE TO LIFE SCIENCE LEADER

Article Submission Guidelines Life Science Leader

Think you have a good idea for an article that Life Science Leader readers would find valuable?  Read these guidelines first before submitting your idea or your article to our editorial director.